Diabetes, a chronic condition that affects millions of people, may have a connection with Alzheimer's disease. Unofficially ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

Advisory group guidance enables nonprofit to be at the forefront of Alzheimer's research WELLESLEY HILLS, MA / ACCESSWIRE / ...

DMTs are expected to account for 73.5% of the global market. The global Alzheimer's disease (AD) market across the eight ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar ...

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Sleep disturbances encompass a broad range of disorders, such as insomnia, restless legs syndrome, parasomnias, sleep-disordered breathing, daytime ...